Skip to content

Faculty profile

Hazel Cheng

Back to faculty
ProfessorDepartment of MedicineUniversity of Toronto

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

  • BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease

    Blood · 2025

  • BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

    Blood · 2025

  • PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease.

    Journal of Clinical Oncology · 2024

All 74 publications

Latest funding

  • CRP-ductin: function and regulation

    NSERC · 1997 · Co-investigator

    $42,000
All 1 grants and awards

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction